Minute Molecular Diagnostics
Minute Molecular Diagnostics (operating as Nuclein) is a molecular diagnostics company that has developed the FDA-cleared, CLIA-waived DASH Rapid PCR System, a point-of-care platform delivering lab-quality PCR results in 15 minutes. The company sells directly to urgent care, pediatric, and primary care clinics and is expanding R&D into transplantation diagnostics.
- Company typePublic
- Founded2017
- HeadquartersEvanston, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Minute Molecular Diagnostics does
Minute Molecular Diagnostics (operating commercially as Nuclein, LLC, headquartered in Austin, Texas) is a molecular diagnostics company founded in 2017 that developed the DASH Rapid PCR System, an FDA-cleared, CLIA-waived point-of-care testing platform. The system delivers lab-quality PCR results within 15 minutes and requires only one minute of hands-on time, addressing the core workflow bottleneck in outpatient clinical settings where traditional lab-based PCR forces patients to await callbacks. The product portfolio consists of two integrated offerings: the DASH Rapid PCR instrument (a compact device with Wi-Fi and cloud connectivity, room-temperature cartridge storage, and a small 15 by 11 by 4 inch footprint) and the DASH SARS-CoV-2 and Flu A/B Test, a multiplex-capable cartridge that detects three respiratory pathogens from a single swab sample.
The company's commercial model is a direct sales approach targeting point-of-care clinical settings including urgent care clinics, pediatric clinics, and primary care clinics, with revenue derived from instrument sales and recurring consumable cartridge purchases. Customer evidence consists of three named mid-market clinical accounts (urgent care in North Carolina, pediatric clinic in North Carolina, primary care clinic in Texas), all citing workflow improvements and ease of use. Pricing is not publicly disclosed and sales are quote-based. Capital structure has evolved through a 2017 seed round ($1.3 million), a 2021 financing ($21.3 million), and a February 2026 registered direct offering (~$26 million) with Lake Street Capital Markets as sole placement agent, with the most recent proceeds earmarked for research and development in the transplantation diagnostics category.
Corporate status is ambiguous across sources: firmographic data lists the company as private with 1-10 employees and a founding location of Evanston, Illinois, while a separate entity reference (Insight Molecular Diagnostics) describes public equity activity around the 2026 offering and lists Austin, Texas as headquarters. The operating entity under the Nuclein brand presents itself as a single-product focused commercial-stage company with an R&D pipeline oriented toward transplantation medicine.
Minute Molecular Diagnostics firmographics
Firmographics- Name
- Minute Molecular Diagnostics
- Legal name
- Insight Molecular Diagnostics
- Website
- https://m2dx.com
- Company type
- Public
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Minute Molecular Diagnostics (operating as Nuclein) is a molecular diagnostics company that has developed the FDA-cleared, CLIA-waived DASH Rapid PCR System, a point-of-care platform delivering lab-quality PCR results in 15 minutes. The company sells directly to urgent care, pediatric, and primary care clinics and is expanding R&D into transplantation diagnostics.
- Ownership category
- akta.pro rank
Minute Molecular Diagnostics industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)
- akta.pro secondary industries
- Point-of-Care (POC) & Rapid Diagnostics (near-patient, lateral flow) (HLAAALAG), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
Keywords
Where Minute Molecular Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Evanston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Minute Molecular Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Revenue model
- DASH Rapid PCR System Sales: Sale of rapid PCR testing instruments and associated test cartridges for point-of-care molecular diagnostics testing in clinical settings
- General Corporate / R&D: Company is currently in growth phase with stock offering to fund operations and R&D activities, particularly in transplantation category
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Minute Molecular Diagnostics product offering
Product offeringCore offering
Minute Molecular Diagnostics (operating as Nuclein) develops and manufactures the DASH Rapid PCR System, an FDA-cleared, CLIA-waived point-of-care molecular diagnostic instrument that delivers lab-quality PCR results in 15 minutes with one minute of hands-on time. The company also sells the DASH SARS-CoV-2 & Flu A/B Test, a multiplex-capable consumable cartridge that detects multiple respiratory pathogens from a single sample, targeting urgent care, pediatric, and primary care clinics.
Product overview
Nuclein offers a focused portfolio of two integrated products: the DASH Rapid PCR System (instrument) and the DASH SARS-CoV-2 & Flu A/B Test (consumable cartridge). The system is a point-of-care molecular diagnostics platform that brings lab-quality PCR testing to the point of care, enabling same-visit diagnosis and treatment decisions. The instrument is designed to be multiplex-capable, allowing the test cartridge to detect multiple pathogens simultaneously from a single sample.
Differentiator
Problem solved
Functional benefit
Products and services
- DASH Rapid PCR System A point-of-care rapid PCR instrument that delivers lab-quality molecular diagnostic results within 15 minutes at the point of care, with only one minute of hands-on time. Features Wi-Fi and cloud connectivity, a small instrument footprint (15"D x 11"H x 4"W), and a multiplex-capable cartridge design. Marketed to clinical settings including urgent care, pediatric, and primary care clinics.
- DASH SARS-CoV-2 & Flu A/B Test FDA-cleared, CLIA-waived multiplex respiratory panel test cartridge that detects SARS-CoV-2 and Influenza A/B from a single sample on the DASH Rapid PCR System, delivering results in 15 minutes. Cartridges are stored at room temperature, eliminating cold chain requirements.
Quantifiable outcome
- Lab-quality results delivered in 15 minutes with 1 minute hands-on time
- +1 more outcomes
Companies that use Minute Molecular Diagnostics
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles1 record
Minute Molecular Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Minute Molecular Diagnostics partnerships and signals
Strategic signalScale indicators4 records
Recent moves5 records
Expansion highlights4 records
Minute Molecular Diagnostics competitors and assessment
Company assessmentEmerging players
- Cue Health: Cue Health offers a connected molecular testing platform for at-home and point-of-care use; it overlaps with DASH on cloud-connected rapid molecular diagnostics.
- binx health: binx health develops rapid molecular diagnostics, including a FDA-cleared multiplex PCR test for chlamydia and gonorrhea at point of care; overlapping technology and POC focus.
- Visby Medical: Visby Medical develops palm-sized PCR devices for rapid infectious disease testing, a similar architectural approach to DASH and a comparable go-to-market in clinical point-of-care settings.
Direct peers
- QuidelOrtho: QuidelOrtho's Sofia and Savanna platforms serve point-of-care diagnostics in outpatient clinics, overlapping with Nuclein's customer base in urgent care and primary care.
- Cepheid (Danaher): Cepheid's GeneXpert Xpress is a leading rapid PCR system for point-of-care settings, including CLIA-waived respiratory assays. It is the most direct competitive comparison for Nuclein's DASH in both technology and target customer.
- Abbott Diagnostics: Abbott's ID NOW is a CLIA-waived rapid molecular platform deployed in urgent care and primary care, directly competing with DASH in the same outpatient respiratory testing workflows.
- bioMérieux (BioFire): BioFire's FilmArray and SpotFire systems offer multiplex molecular diagnostics for point-of-care use; SpotFire in particular competes head-to-head with DASH on rapid multiplex respiratory panels.
- Roche Diagnostics (cobas Liat): Roche's cobas Liat is a compact, rapid PCR system delivering results in ~20 minutes, marketed to urgent care and physician offices. It is a direct competitor on form factor and clinical use case.
Broad incumbents
- Mesa Labs: Mesa Labs owns rapid diagnostic product lines (e.g., Accula) and serves clinical point-of-care markets, providing a broader incumbent comparison to Nuclein's rapid PCR platform.
- QIAGEN: QIAGEN is a large molecular diagnostics and sample-prep vendor with point-of-care PCR offerings (e.g., QIAstat-Dx); relevant incumbent comparable given shared molecular diagnostic technology stack.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Minute Molecular Diagnostics social profiles
Digital presenceMinute Molecular Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Minute Molecular Diagnostics leadership team
Management profileNumber of profiles
Profiles2 records
Minute Molecular Diagnostics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Minute Molecular Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Minute Molecular Diagnostics
What does Minute Molecular Diagnostics do?
Minute Molecular Diagnostics (operating as Nuclein) develops and manufactures the DASH Rapid PCR System, an FDA-cleared, CLIA-waived point-of-care molecular diagnostic instrument that delivers lab-quality PCR results in 15 minutes with one minute of hands-on time. The company also sells the DASH SARS-CoV-2 & Flu A/B Test, a multiplex-capable consumable cartridge that detects multiple respiratory pathogens from a single sample, targeting urgent care, pediatric, and primary care clinics.
Is Minute Molecular Diagnostics a public or private company?
Minute Molecular Diagnostics is a public company. It is classified as venture growth investor backed and is currently operating.
When was Minute Molecular Diagnostics founded?
Minute Molecular Diagnostics was founded in 2017. It employs 1 to 10 people.
Where is Minute Molecular Diagnostics based?
Minute Molecular Diagnostics is headquartered in Evanston, United States, in the North America region.
How does Minute Molecular Diagnostics make money?
Two revenue lines are on record. DASH Rapid PCR System Sales are the primary driver. The others are general Corporate / R&D.
Who are Minute Molecular Diagnostics's main competitors?
Emerging players on record are Cue Health, binx health and Visby Medical. Direct peers are QuidelOrtho, Cepheid (Danaher), Abbott Diagnostics, bioMérieux (BioFire) and Roche Diagnostics (cobas Liat). Broad incumbents are Mesa Labs and QIAGEN.
Does Minute Molecular Diagnostics have an API?
No public API is recorded for Minute Molecular Diagnostics.
What industry is Minute Molecular Diagnostics in?
Minute Molecular Diagnostics's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAOAI, Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges), with a secondary code of HLAAALAG, Point-of-Care (POC) & Rapid Diagnostics (near-patient, lateral flow). Its NAICS code is 325413 and its SIC code is 2835.